Target intelligence / Profile preview

RNA, U6atac small nuclear 42, pseudogene (RNU6ATAC42P)

Target
RNU6ATAC42P
Molecular classification
Pseudogene, Non-coding RNA (pseudogene-derived), Other
01

Overview

RNU6ATAC42P is a **pseudogene** of the U6atac small nuclear RNA family, specifically designated as the 42nd such pseudogene. U6atac small nuclear RNAs are involved in the minor spliceosome, a complex responsible for the removal of rare U12-type introns from pre-mRNA transcripts. However, as a pseudogene, RNU6ATAC42P is a non-functional genomic remnant that arose from duplication or retrotransposition events. It is not known to produce a functional RNA or protein product, nor does it act as a receptor, enzyme, transporter, or other canonical therapeutic target. Like some pseudogenes, it may have the potential to modulate gene expression through antisense regulation or act as a source of regulatory RNAs if transcribed, but there is no direct evidence for biological function or disease relevance unique to RNU6ATAC42P. **Key points:** - **RNU6ATAC42P** is a **pseudogene**—a non-functional, typically non-expressed genomic DNA sequence related to a functional small nuclear RNA gene. - It is *not* a protein, receptor, enzyme, transporter, or validated therapeutic target. - There are no known drugs, therapeutic mechanisms, safety, or biomarker associations directly linked to this pseudogene. - Its main classification is as a **non-coding RNA pseudogene**; it does not encode a functional small nuclear RNA. - Alternative names are limited, as it is a pseudogene with a standardized nomenclature. This pseudogene should not be considered for drug targeting, therapeutic intervention, or biomarker use barring specific new evidence. Any reference to it as a target is likely due to a misinterpretation of gene classification nomenclature or sequence similarity to functional small nuclear RNAs.

Other names
RNU6ATAC42PRNA, U6atac small nuclear 42, pseudogene
02

Mechanism of action

Not applicable for drugs; for pseudogenes in general, possible regulatory effects via antisense transcripts or acting as competitive endogenous RNAs/miRNA sponges, but not specifically shown for this gene

03

Biological functions

May have regulatory potential as a pseudogene transcript (possible roles as antisense RNA or source of small interfering RNA)No direct catalytic or structural cellular function, as it is a pseudogene
04

Disease associations

No direct, established disease association; pseudogenes in general can be involved in gene regulation, but specific evidence for this pseudogene is lackingOther (possible regulatory or biomarker role if studied in detail)

Beyond the preview

Go deeper on RNA, U6atac small nuclear 42, pseudogene (RNU6ATAC42P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6atac small nuclear 42, pseudogene (RNU6ATAC42P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call